ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2022

1:00PM-3:00PM: Abstract Number: 1869

Looking for BlyS(BAFF) in Juvenile Dermatomyositis: A New Biomarker of Disease Activity

Muscle Biology, Myositis and Myopathies Poster II

1:00PM-3:00PM: Abstract Number: 2010

Lowering Expectations: Glucocorticoid Tapering Among Veterans with Rheumatoid Arthritis Achieving Low Disease Activity on Stable Biologic Therapy

RA – Treatment Poster IV

1:00PM-3:00PM: Abstract Number: 2032

Major Salivary Gland Ultrasound and Elastography for Assessment of Disease Activity in Patients of Primary Sjögren’s Syndrome

Sjögren's Syndrome – Basic and Clinical Science Poster

1:00PM-3:00PM: Abstract Number: 1984

Malignancies Risk in Rheumatoid Arthritis Patients Treated with Tofacitinib or TNF Inhibitors, a National Study: RELATION Study

RA – Treatment Poster IV

1:00PM-3:00PM: Abstract Number: 1683

Malondialdehyde-Acetaldehyde (MAA) Modified Matrix Gla Protein (MGP) Increases Citrullination by Human Macrophages

Innate Immunity Poster: Basic and Translational Science

1:00PM-3:00PM: Abstract Number: 1749

Mass Spectrometry-Based HLA Peptidomics Analysis Reveals Both Expected and Novel Citrullinated Antigen Targets in Rheumatoid Arthritis

T Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster

1:00PM-3:00PM: Abstract Number: 1942

Maybe Silent: Spine Disease in Chronic Recurrent Multifocal Osteomyelitis, Clinical Features, Risk Factors, and Red Flags

Pediatric Rheumatology – Clinical Poster III: Other

1:00PM-3:00PM: Abstract Number: 1697

Measurements of Specific Activation Through the Lectin -or Classical Pathway of Complement in Patients with SLE

Innate Immunity Poster: Basic and Translational Science

1:00PM-3:00PM: Abstract Number: 2066

Measuring Sexual Dysfunction as an Indicator of Frailty in Systemic Lupus Erythematosus Population

SLE – Diagnosis, Manifestations, and Outcomes Poster III: Outcomes

1:00PM-3:00PM: Abstract Number: 2063

Medication Cost Concerns and Disparities in Patient-reported Outcomes Among a Multiethnic Cohort of Patients with Lupus

SLE – Diagnosis, Manifestations, and Outcomes Poster III: Outcomes

1:00PM-3:00PM: Abstract Number: 1947

Medication Use in Childhood Sjogren Disease

Pediatric Rheumatology – Clinical Poster III: Other

1:00PM-3:00PM: Abstract Number: 2078

Mesangial Lupus Nephritis: Long Term Outcomes

SLE – Diagnosis, Manifestations, and Outcomes Poster III: Outcomes

1:00PM-3:00PM: Abstract Number: 2040

Metformin Improves Objective Measures of Dry Eyes and Focus Score in Sjögren′s Disease: A Retrospective Observational Study

Sjögren's Syndrome – Basic and Clinical Science Poster

1:00PM-3:00PM: Abstract Number: 1991

Mice Do Not Develop CIA: Knocking out of Kv1.3 Renders CD4+TEMCells Resistant to Activation

RA – Treatment Poster IV

1:00PM-3:00PM: Abstract Number: 2131

Minimal Disease Activity Response Patterns in Bio-Naïve Patients Treated with Guselkumab: A Machine Learning Analysis

Spondyloarthritis Including PsA – Treatment Poster III: PsA

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].